Supernus Pharmaceuticals, Inc.
SUPNNASDAQHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 15, 2026 close
- Market cap
- $2.30B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $39.97$59.68
- Volume (live)
- -
- Avg. volume (3M)
- 687.07K
Supernus Pharmaceuticals (SUPN) Stock Price & Financial Analysis
Supernus Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $39.41 - $41.20 |
|---|---|
| 52-Week High | $59.68 |
| 52-Week Low | $39.97 |
| Open | $40.88 |
| Volume (last close) | 1.01M |
| Average Volume (3M) | 687.07K |
| Revenue (TTM) | 830.44M |
|---|---|
| Net Income (TTM) | -109.89M |
| Free Cash Flow (TTM) | 18.79M |
| EPS (TTM) | −$1.91 |
| Profit Margin | -13.23% |
| Operating Margin | -6.85% |
| Return on Equity (ROE) | -10.66% |
| Debt to Equity | 0.04 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 2.30B |
|---|---|
| Shares Outstanding | 58.07M |
| Price to Sales (P/S) | 2.77 |
| Price to Book (P/B) | 2.23 |
| EV/EBITDA | -118.93 |
| 50-Day MA | $44.16 |
|---|---|
| 200-Day MA | $47.88 |
| 1-Year Change | −20.48% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Supernus Pharmaceuticals at a Glance
As of the Oct 15, 2026 close, Supernus Pharmaceuticals (SUPN) has a market capitalization of $2.30B. The stock trades at 2.8× sales. Over the trailing twelve months it lost $109.89M on revenue of $830.44M and generated $18.79M of free cash flow. Revenue grew 24.9% year over year.
As of its latest reported balance sheet, it holds $179.95M in cash and securities against $40.17M of debt, a net cash position of $139.78M.
Supernus Pharmaceuticals does not currently pay a dividend.
The share price is down 20.5% over the past year. At $39.57 (the Oct 15, 2026 close) it sits near the bottom of its 52-week range of $39.97 to $59.68, below its 200-day moving average of $47.88.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $65.50, 65.5% above the Oct 15, 2026 close.
Frequently Asked Questions About Supernus Pharmaceuticals
What is the current stock price for SUPN?
As of the Oct 15, 2026 close, SUPN stock trades at $39.57. The 52-week range is $39.97–$59.68, with a day range of $39.41–$41.20.
What is the P/E ratio for SUPN?
The P/E ratio (Price-to-Earnings) for SUPN is shown in the Key Statistics section. This valuation metric helps compare Supernus Pharmaceuticals, Inc. to industry peers.
Does SUPN pay dividends?
Supernus Pharmaceuticals does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for SUPN?
Based on ratings from 4 professional analysts over the last 90 days, the consensus for SUPN is Buy. The average 12-month price target is $65.50, a 65.5% upside from the Oct 15, 2026 close of $39.57.
What is the market cap of SUPN?
As of the Oct 15, 2026 close, Supernus Pharmaceuticals's market capitalization is $2.30B, classifying it as a mid-cap company. Supernus Pharmaceuticals operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.